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OBJECTIVES We sought to compare the tolerability and safety of three fixed doses of ximelagatran versus
warfarin in patients with nonvalvular atrial fibrillation (NVAF).
BACKGROUND Anticoagulants such as warfarin lower the risk of stroke in patients with NVAF. Ximelagatran
is a novel, oral direct thrombin inhibitor with predictable pharmacokinetics and no known
food or pharmacokinetic drug interactions.
METHODS This was a 12-week, randomized, parallel-group, dose-guiding study of NVAF patients with
at least one additional risk factor for stroke. The primary end point was the number of
thromboembolic events and bleedings. Three groups received ximelagatran (n  187) at 20,
40, or 60 mg twice daily, given in a double-blind fashion, without routine coagulation
monitoring. In a fourth group, warfarin (n  67) was managed and monitored according to
normal routines, aiming for an International Normalized Ratio of 2.0 to 3.0.
RESULTS A total of 254 patients received study drug. One ischemic stroke (nonfatal) and one transient
ischemic attack (TIA) occurred in the ximelagatran group. Two TIAs occurred in the
warfarin group. No major bleeds were observed in the ximelagatran group. One major bleed
occurred in a warfarin-treated patient. The number of minor and multiple minor bleeds was
low, but there was a slight increase by ximelagatran dose. The 60-mg dose resulted in the
same number of bleeding events as that with warfarin. S-alanine aminotransferase was
increased in eight patients (4.3%) taking ximelagatran, but normalized with continuous
treatment or cessation of the drug.
CONCLUSIONS Fixed oral doses of ximelagatran up to 60 mg twice daily were well tolerated, without the need
for dose adjustment or coagulation monitoring. (J Am Coll Cardiol 2003;41:1445–51)
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Atrial fibrillation (AF) is the most frequent arrhythmia in
clinical practice and is the strongest independent risk factor
for stroke (1,2). Approximately 50% of all cardiogenic and
systemic emboli occur in individuals with AF. Atrial fibril-
lation occurs in 1% of individuals below 50 years of age,
increasing to up to 10% in people over 75 years of age (3).
Stroke occurs in approximately 5% of the nonvalvular AF
(NVAF) patient population in the range of two to seven
times that of people without AF, but this figure increases to
12% if the patient has had a previous stroke or transient
ischemic attack (TIA) (2).
The benefits of treatment with oral warfarin in reducing
the risk of stroke in patients with NVAF have been well
established by multiple randomized trials. In a meta-analysis
of five studies, anticoagulation with warfarin produced a
62% relative risk reduction for stroke, compared with
placebo (4–9), and this benefit accrued for either primary or
secondary prevention (10,11). Indeed, long-term oral anti-
coagulation therapies in patients with NVAF who have one
or more additional risk factors for stroke are supported by
several published guidelines (3,12).
Aspirin at doses between 75 and 325 mg/day has also
been reported to reduce the risk of stroke in patients with
NVAF, although the risk reduction is less than that with
warfarin. In one meta-analysis, the relative risk reduction for
stroke was 22% after aspirin treatment compared with
placebo (4). Current treatment guidelines therefore suggest
aspirin rather than warfarin for NVAF patients with a low
risk of stroke (i.e., those 60 years of age or those without
additional risk factors) (3,12). Higher risk patients who are
treated with aspirin instead of warfarin remain at a signif-
icant disadvantage in terms of ongoing stroke risk (4).
Ximelagatran (Exanta; AstraZeneca, Mo¨lndal, Sweden)
is a novel, oral direct thrombin inhibitor that inhibits the
final step in the coagulation process—namely, the conver-
sion of fibrinogen to insoluble fibrin by thrombin. Ximel-
agatran is converted to its active form, melagatran, after oral
administration. Consistent pharmacokinetic properties
make the need for dose titration or routine coagulation
monitoring unnecessary, creating advantages that are likely
to increase compliance with ximelagatran treatment com-
pared with currently available anticoagulants (13). This
12-week study of ximelagatran in patients with chronic
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NVAF with a medium to high risk of stroke is the first to
investigate the tolerability (with special regard for throm-
boembolic events and bleedings) and safety of three fixed,
oral doses of ximelagatran (20, 40, and 60 mg twice daily)
compared with dose-adjusted warfarin (aiming for an In-
ternational Normalized Ratio [INR] of 2.0 to 3.0).
METHODS
Patients. Patients at least 18 years of age with a history of
chronic, i.e., intermittent (paroxysmal) or persistent NVAF
verified by at least two electrocardiograms within the pre-
vious year, plus at least one of the defined risk factors for
stroke and without any of the exclusion criteria listed in
Table 1, were enrolled into the study. Treatment with either
nonsteroidal anti-inflammatory drugs or fibrinolytic agents
within the week before the start of the study was prohibited.
Aspirin was not recommended in the study, but low doses
(up to 160 mg/day) could be used at the investigators’
discretion. Apart from the drugs previously specified, no
other drugs were prohibited.
Study protocol. The Stroke Prevention by ORal Throm-
bin Inhibitor in atrial Fibrillation (SPORTIF II) trial was a
prospective, multicenter, randomized, parallel-group, dose-
guiding study performed at 37 centers in 11 countries in
Europe and U.S. The duration of the study was 12 weeks.
Patients were randomized using a computer-generated
schema into four groups, resulting in a 1:1:1:1 block
randomization. Complete blocks were distributed to the
centers, from which patients were allocated in consecutive
order. Patients in three groups received fixed doses of 20,
40, or 60 mg twice daily of oral ximelagatran in a double-
blinded manner. No loading doses or dose titrations were
used. Dose-adjusted warfarin (aiming for an INR of 2.0 to
3.0) was given to the fourth group in an open-label fashion
and managed according to each center’s normal clinical
routine (Fig. 1).
Patients previously receiving warfarin and who were
randomized to ximelagatran interrupted warfarin treatment
and began ximelagatran once the INR value was at or below
1.5. This was achieved by taking no drug at all, by receiving
2 mg vitamin K orally to reverse the effect of warfarin, or by
administering low-molecular-weight or unfractionated hep-
arin until the INR had reached 1.5 or below. At the end of
the study, patients who stopped ximelagatran began warfa-
rin therapy 12 to 24 h after the last dose of ximelagatran.
After a two-week run-in period, all patients attended the
clinic at randomization, at 0.5, 1, 2, 4, 8, and 12 weeks of
treatment, and 2 weeks after cessation of treatment. Local
ethics committees approved the study, and all patients gave
written, informed consent to participate in the study. The
study was performed in accordance with the ethical princi-
ples defined in the Declaration of Helsinki.
End points and outcome events. All strokes and TIAs
that occurred during the study were assessed centrally by
computed tomography or magnetic resonance imaging scans
and classified by an independent neuroradiologist blinded to
study treatment as ischemic, ischemic with hemorrhagic
transformation, or primary hemorrhagic stroke. The severity
of the stroke was assessed according to the modified Rankin
scale (14) and the Barthel index of activities of daily living
(15) three months after the event.
Safety was assessed by monitoring for bleeding events and
adverse events (AEs), clinical chemistry, hematology, uri-
Abbreviations and Acronyms
AE  adverse event
AF  atrial fibrillation
aPTT  activated partial thromboplastin time
Fe-Hb  fecal hemoglobin
INR  International Normalized Ratio
NVAF  nonvalvular atrial fibrillation
S-ALAT  S-alanine aminotransferase
SPORTIF  Stroke Prevention by ORal Thrombin
Inhibitor in atrial Fibrillation trial
TIA  transient ischemic attack
U-Hb  urinary erythrocytes (hemoglobin)
Table 1. Summary of Principal Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
History of hypertension Stroke and/or systemic embolism within the previous 2 years
Age 65 yrs Conditions associated with increased risk of bleeding
Previous stroke or TIA NVAF secondary to other reversible disorders (e.g., thyrotoxicosis)
Previous systemic embolism Presence of mechanical heart valves
Left ventricular dysfunction Myocardial infarction, CABG, or PTCA within previous 3 months
(either LVEF 40% or Diagnosis of left ventricular aneurysm or atrial myxoma
symptomatic CHF Treatment with either NSAIDs or fibrinolytics within previous week
within 3 months) Renal impairment (calculated creatinine clearance 40 ml/min)
Diabetes mellitus Systolic/diastolic blood pressure 180/100 mm Hg
Coronary heart disease History of rheumatic fever
Liver insufficiency
Hemoglobin 100 g/l or platelet count 100,000
Contraindications to warfarin treatment
CABG  coronary artery bypass grafting; CHF  congestive heart failure; LVEF  left ventricular ejection fraction; NSAIDs
 nonsteroidal anti-inflammatory drugs; PTCA  percutaneous transluminal coronary angioplasty; TIA  transient ischemic
attack.
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nary erythrocytes (U-Hb), and fecal hemoglobin (Fe-Hb).
Blood samples for safety parameters (i.e., hematology and
clinical chemistry) were taken at baseline and at 2, 4, 8, and
12 weeks. A central laboratory (BARC Laboratory, Ghent,
Belgium) analyzed all samples. Bleeding events were iden-
tified by three methods—specific questioning at each visit;
AE reporting; and review of the clinical laboratory reports—
and were categorized as major or minor according to the
following criteria: 1) clinically overt; 2) critical site (e.g.,
intracranial, retroperitoneal, intraocular, spinal, or pericar-
dial); 3) bleeding index (number of units transfused and a
drop of 2.0 Hb [g/dl] before and after the bleed); and 4)
need for medical or surgical intervention.
A “major bleed” was defined as satisfying criterion 1 in
combination with any of criteria 2, 3, or 4, and a “minor
bleed” as satisfying criterion 1 and none of criteria 2, 3, or
4. Bleeding detected by U-Hb and Fe-Hb dipstick testing
was reported separately.
An independent Data Safety Monitoring Board (DSMB)
was established to monitor patient safety in the study (i.e.,
all AEs, withdrawals, major bleeds, and strokes/TIAs). The
DSMB reviewed the progress of the study for safety
concerns after 100, 200, and 400 patient-months of drug
treatment. The DSMB could recommend to the principal
investigator and the sponsor whether or not study treatment
should be terminated for any safety concerns.
Pharmacokinetics and pharmacodynamics. The pharma-
cokinetic data from this study will be reported separately
(16). The pharmacodynamic profiles of both ximelagatran
and warfarin were investigated using activated partial
thromboplastin time (aPTT) and INR assays, respectively.
For patients receiving ximelagatran, aPTT was analyzed
centrally (BARC Laboratory). For those receiving warfarin,
the INR was analyzed locally.
Statistical analysis. The tolerability and safety of the three
ximelagatran dose levels were assessed exploratively, with
the warfarin group as a reference. Data from a sample size
of a total of 220 patients randomized in equal numbers to
one of three different dose levels of ximelagatran or warfarin
to achieve 50 evaluable patients in each of the four treat-
ment groups was considered sufficient to allow for the
detection of important tolerability and safety events (e.g.,
those with minor and major bleeding during any of the four
treatment regimens), although no formal statistical power
calculation was performed for this dose-guiding study. All
statistical analyses were prespecified before the study treat-
ment code was broken. In this primary analysis, the number
of thromboembolic events, bleeding, and safety were com-
pared. Descriptive statistics were used in the study, accord-
ing to the intention-to-treat principle. The final statistical
analyses and reporting of the data were performed by the
sponsor in collaboration with the authors.
RESULTS
Patient demographics. A total of 257 outpatients were
randomized into the study over a period of approximately
four months, and 254 patients began treatment. Patient
demographic data were well balanced across the four treat-
ment groups (Table 2). The mean age of the patients was
69.5 years (range 39 to 95), 72% of whom were at least 65
years of age and 27% aged 75 years or older. There were 154
males in the study. Atrial fibrillation was present for more
than a year in 73% of patients prior to enrollment and was
persistent in 94% of patients. Cardioversion had been
attempted before entry in 34% of the patients.
Patients’ past or current medical histories and concomi-
tant medication usage were evenly distributed across the
Figure 1. Design and treatment dosages of the SPORTIF II study. bid  twice daily; INR  International Normalized Ratio.
1447JACC Vol. 41, No. 9, 2003 Petersen et al.
May 7, 2003:1445–51 Ximelagatran in Patients With AF
treatment groups. The most common current medical
conditions were hypertension (57%), coronary heart disease
(43%), left ventricular dysfunction (31%), and diabetes
mellitus (21%). During the study, patients took beta-
blockers, angiotensin-converting enzyme inhibitors, and
calcium antagonists. At study entry, 155 patients (61%) had
taken vitamin K antagonists, and 45 (18%) used aspirin at
entry, compared with 4 patients (2%) during the trial.
In addition to NVAF, all but one of the patients (99.6%)
had at least one additional risk factor for stroke or TIA, 75%
of patients had at least two additional risk factors, 42% had
three or more risk factors, and one patient had six risk
factors (Table 2), thus indicating a moderate- to high-risk
patient population. The most common combinations of risk
factors in addition to NVAF were age 65 years (14.6%),
age 65 years and hypertension (11.8%), age 65 years,
hypertension and coronary heart disease (7.1%), and hyper-
tension (4.7%).
Patient disposition. Of 257 patients randomized, 207
completed the study. Forty-seven patients discontinued
assigned treatment prematurely, 18 owing to AEs. There
was no notable difference in the rates of withdrawal from
the ximelagatran and warfarin groups. Four patients discon-
tinued for more than one reason. One patient in the 20-mg
ximelagatran group and two patients in the warfarin group
discontinued due to AEs and a lack of eligibility criteria.
One patient in the 60-mg ximelagatran group did not meet
the eligibility criteria and was withdrawn from drug treat-
ment.
Compliance. Mean compliance was 100%, 96%, and 98%
for the 20-, 40-, and 60-mg ximelagatran groups, respec-
tively, as assessed by returned tablet counts.
Warfarin control. Attainment of optimal INR values (2.0
to 3.0) increased from 34% of patients at the start of the
study to 57% after 12 weeks (Fig. 2). The INR was also
assessed, off-protocol, in two patients receiving ximelagat-
ran who had an INR of approximately 2.0.
Clinical events. No systemic embolic events were reported
during the study. Four neurologic events occurred, one of
which was a nonfatal ischemic stroke and the other three
TIAs (Table 3). The patient experiencing an ischemic
stroke had five risk factors in addition to NVAF (previous
TIA, hypertension, coronary heart disease, left ventricular
dysfunction, and diabetes mellitus); he was assigned to 60
mg ximelagatran and has developed persistent aphasia. The
three patients who experienced TIA were older than 65
years of age. One patient who received warfarin had four
additional risk factors (65 years of age, hypertension, left
ventricular dysfunction, and diabetes mellitus), and two had
one risk factor (65 years of age). None were taking aspirin
before or during the study.
The total number of bleeds was low in all four treatment
groups. No fatal or critical-site bleeds occurred. Of the 254
patients who received the study drug, 231 (91%) experi-
enced no bleeding. One major bleed (vaginal) occurred after
two months of warfarin treatment in an 82-year-old female
patient, who recovered without sequelae. No major bleeding
occurred in the patients taking ximelagatran.
Minor and multiple minor bleeds consisted mainly of
hematuria, purpura, epistaxis, hematomas after venipunc-
ture, gingival bleeding, or rectal bleeding. These occurred in
four, five, and seven patients receiving ximelagatran 20-,
40-, and 60-mg, respectively, compared with six patients in
the warfarin group. Figure 3 represents the time of onset
and cumulative number of patients experiencing any bleed-
ing since randomization. Numerically, there were fewer
bleeds in the 20- and 40-mg ximelagatran treatment groups,
compared with the 60-mg ximelagatran and warfarin
groups, and they accumulated more slowly during the
12-week treatment period in this study. Most bleeds in the
latter two groups occurred within two weeks after the start
of the study. There was no statistically significant correla-
tion between bleeding and either creatinine clearance or age
in any of the four groups.
General safety. In general, both ximelagatran and warfarin
were well tolerated in this NVAF patient population. In
total, 97 (51.9%) and 33 (49.3%) patients in the ximelagat-
ran and warfarin groups, respectively, did not report any













Median age (yrs) 70 69 69 71 70
Mean weight (kg) 85 85 82 80 83
Males (%) 65 68 54 55 61
History of hypertension (%) 62 55 61 51 57
No. of risk factors in addition to AF, n (%)
0 0 0 0 1 (1) 1 (0)
1 15 (23) 19 (31) 12 (20) 17 (25) 63 (25)
2 24 (36) 23 (37) 16 (27) 20 (30) 83 (33)
3 16 (24) 10 (16) 21 (36) 15 (22) 62 (24)
4 6 (9) 8 (13) 7 (12) 12 (18) 33 (13)
5 4 (6) 2 (3) 3 (5) 2 (3) 11 (4)
6 1 (2) 0 0 0 1 (0)
AF  atrial fibrillation; bid  twice daily; INR  International Normalized Ratio.
1448 Petersen et al. JACC Vol. 41, No. 9, 2003
Ximelagatran in Patients With AF May 7, 2003:1445–51
AEs. During active treatment, AEs were reported by 90
ximelagatran-treated patients (48.1%) and 34 warfarin-
treated patients (50.7%). None of the AEs were dose-
related. A total of 16 patients (8.6%) discontinued ximel-
agatran, and six patients (9%) discontinued warfarin therapy
due to AEs. The most common AEs experienced by
patients are detailed in Table 4. One patient (82 years old)
with a medical history of hypertension, chronic bronchitis,
gastritis, colic, agitation, and hypokalemia, who received 20
mg ximelagatran, died from multiorgan failure, secondary to
lung disease, but this was considered unlikely to be related
to ximelagatran.
Eight of 187 patients (4.3%) experienced a transient
increase in liver enzymes, defined as a level of S-alanine
aminotransferase (S-ALAT) above three times the upper
limit of normal, after four to eight weeks of treatment with
ximelagatran. The S-ALAT levels normalized with contin-
ued treatment in five patients and after drug withdrawal in
three patients. All eight patients were asymptomatic, and
the elevations did not appear to be dose-related. No patient
on warfarin showed a similar increase in S-ALAT levels.
Urine erythrocytes (U-Hb) were positive in 22 patients
(i.e., 5, 5, 4, and 8 patients in the 20-, 40-, and 60-mg
ximelagatran, and warfarin treatment groups, respectively).
Fecal hemoglobin was seen in a total of 22 patients (i.e., 6,
4, 7, and 5 patients in the 20-, 40-, and 60-mg ximelagat-
ran, and warfarin treatment groups, respectively). Thus,
there was no real difference between the different doses of
ximelagatran compared with warfarin. No other significant
clinical or laboratory abnormalities were seen.
Pharmacodynamics. The aPTT increased with increasing
ximelagatran doses; there was a nonlinear relation to the
plasma concentration of melagatran (r2  0.43).
DISCUSSION
The oral direct thrombin inhibitor ximelagatran has previ-
ously been found to be efficacious and well tolerated for the
prevention of deep vein thrombosis in patients undergoing
orthopedic surgery (17,18). SPORTIF II is the first long-
term treatment study of ximelagatran in fixed, oral doses for
the prevention of stroke and systemic embolic events in
patients with NVAF. The study population was similar to
previous larger cohorts of patients with NVAF in studies of
warfarin for stroke prevention, with patient characteristics
balanced across the four treatment groups. All but one of
Figure 2. Proportion of patients taking warfarin within defined International Normalized Ratio (INR) ranges, as determined at a central laboratory.
Table 3. Characteristics of Patients Experiencing Stroke or TIA





Ximelagatran (60 mg bid) Male 63 Ischemic* No Yes
Male 65 TIA No No
Warfarin Male 73 TIA No No
Female 71 TIA No No
*This patient had four risk factors for stroke: previous TIA, hypertension, left ventricular dysfunction, and diabetes.
bid  twice daily; TIA  transient ischemic attack.
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the patients in the randomized population had at least one
additional risk factor for stroke or TIA and would therefore
be selected for long-term oral anticoagulation, according to
current treatment guidelines.
Owing to treatment with warfarin prior to inclusion into
the study, 34% of warfarin-treated patients had INRs within
the target range at the initiation of the study. However, the
INR improved with time, and approximately two-thirds of
the warfarin group was maintained in the therapeutic
window of an INR of 2.0 to 3.0 at the end of the study.
Based on earlier observations, INR levels seem to improve
in patients under controlled conditions, such as in clinical
trials. This study documents that control of warfarin levels
was consistent with what might be expected in a well-run
anticoagulation clinic. The INR assays are designed to
evaluate the effect of warfarin on the activity of vitamin
K–dependent coagulation factors and cannot be used to
monitor therapy with thrombin inhibitors such as ximel-
agatran (19). Our experience and data from this study,
undertaken without dose adjustment or coagulation moni-
toring and with no increase in bleeding events in
ximelagatran-treated patients during 12 weeks of treatment,
support the evaluation of ximelagatran without routine
coagulation monitoring in larger trials of patients with
NVAF.
Two clinical events (one TIA and one nonfatal ischemic
stroke) occurred in patients receiving ximelagatran (both in
the 60-mg group), and two events (TIA) occurred in the
warfarin group. There were no thromboembolic events in
the 20- or 40-mg ximelagatran groups and no systemic
embolic events in any patient group. Interpretation of these
findings from this short-term study is limited, and long-
term studies involving considerably larger patient popula-
tions are ongoing.
Bleeding is an expected AE in trials of anticoagulant
drugs, and in this respect, there was no significant difference
between ximelagatran and warfarin during this 12-week
study. There was a slightly higher rate of minor bleeding
with increasing ximelagatran dose, although no statistically
significant differences were detected between the groups,
and the same number of bleeding events occurred in the
60-mg ximelagatran group as in the warfarin group. No
obvious clinical factors (e.g., age, body weight, creatinine
clearance) identified patients susceptible to bleeding during
treatment.
Asymptomatic elevation in S-ALAT levels developed in
4.3% of patients treated with ximelagatran after four to
eight weeks. All values normalized whether treatment was
interrupted or continued. The mechanism of action respon-
sible for this finding is not understood, but a similar
experience has been reported with unfractionated and low-
molecular-weight heparins (20). This phenomenon is being
Figure 3. Cumulative number of patients by treatment group who developed minor, multiple minor, and major bleeding during the study.








Hematuria 11 (5.9) 7 (10.4)
Dizziness 7 (3.7) 3 (4.5)
Pain 7 (3.7) 0
Diarrhea 6 (3.2) 0
Bruising* 6 (3.2) 1 (1.5)
Accident and/or injury 5 (2.7) 0
Headache 5 (2.7) 2 (3.0)
Nausea 5 (2.7) 1 (1.5)
*E.g., hematoma following venepuncture. Data are presented as the number (%) of
patients.
AE  adverse events; INR  International Normalized Ratio.
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further investigated in ongoing and planned long-term
studies of ximelagatran.
Conclusions. Fixed, oral doses of ximelagatran up to 60
mg twice daily were well tolerated, without the need for
dose adjustments or coagulation monitoring, during a three-
month treatment period in NVAF patients at risk for stroke
and systemic embolism. This small, dose-guiding study has
several limitations, including a small sample size, a short
assessment period, and noncentrally adjudicated bleeding
events (although this would be expected to reduce the
number of bleeding events reported). In addition, as warfa-
rin was given in an open-label fashion, there may have been
a potential for bias. However, larger clinical trials are
ongoing to compare ximelagatran with warfarin for long-
term prophylaxis against stroke and systemic embolic events
in patients with AF.
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